<DOC>
	<DOC>NCT01067781</DOC>
	<brief_summary>The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo</brief_summary>
	<brief_title>Gender-Stratified Safety and Immunogenicity Study</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. A female or male 1864 (inclusive) years of age; 2. In good health as determined by medical history and screening exam; 3. Females who are postmenopausal, surgically sterile, or have a negative serum/urine pregnancy test at Day 0 and agree not to become pregnant for the duration of study. 1. Abnormalities at physical exam [as determined by the Toxicity Grading Scale (Grade 14)]; 2. Laboratory abnormalities [as determined by the Toxicity Grading Scale (Grade 1 4)] at screening; 3. Participated in research involving investigational product within 30 days before planned date of first vaccination; 4. Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd; 5. Women who are pregnant or breastfeeding; 6. Clinically significant underlying enteric, pulmonary, cardiac or renal disease; 7. Current seizure disorder; 8. Current use of immunosuppressive therapy (inhaled steroids are allowed); 9. Known or suspected alcohol abuse or illicit drug use within the last year; 10. Positive Serology for HIV1, HIV2, HbsAg, or HCV; 11. Known allergies to any component of the vaccine including adhesives; 12. An employee of the study site; 13. An employee of Intercell (global) or an immediate family member; 14. Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; 15. Receipt of any routine vaccinations within 7 days prior to, or following, the date of planned study vaccinations.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Prevention of Travelers' Diarrhea</keyword>
</DOC>